merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Because the vials are FDA‑approved and marketed as a safer, lower‑priced alternative to unregulated compounded drugs.</answer>
<question_number>2</question_number>
<answer>It provides online prescriptions and direct sales of approved vials, bypassing third‑party supply chains and undercutting telehealth firms that sell compounded meds.</answer>
<question_number>3</question_number>
<answer>Lack of FDA oversight leading to safety, quality, and effectiveness concerns.</answer>
<question_number>4</question_number>
<answer>By offering a cheaper, approved option it can attract patients away from pens and from compounded drugs, recapturing share even if it cannibalizes its own pen sales.</answer>
<question_number>5</question_number>
<answer>When tirzepatide is removed from the FDA shortage list, it limits the market for mass compounding, supporting Lilly’s legal actions against compounding pharmacies.</answer>
<question_number>6</question_number>
<answer>It shows a move toward transparent, direct‑to‑consumer pricing by selling the drug itself and eliminating third‑party intermediaries.</answer>
<question_number>7</question_number>
<answer>Since Medicare does not cover weight‑loss drugs, older patients may turn to the lower‑cost vials, increasing demand for Lilly’s offering.</answer>
<question_number>8</question_number>
<answer>Patients may view the FDA‑approved vials as a safer alternative to compounded tirzepatide.</answer>
<question_number>9</question_number>
<answer>It is listed by the FDA as “in shortage,” which permits compounding pharmacies to make copycat versions.</answer>
<question_number>10</question_number>
<answer>Lowering the price of its own vials to undercut the compounding market.</answer>